Alimentary Tract: Clinical ResearchA Randomized Formula Controlled Trial of Bifidobacterium lactis and Streptococcus thermophilus for Prevention of Antibiotic-Associated Diarrhea in InfantsCorrêa, Naflesia B. O MD*; Péret Filho, Luciano A MD, PhD*; Penna, Francisco J MD, PhD*; Lima, Fátima M. L. S MD†; Nicoli, Jacques R PhD‡Author Information From *Departamento de Pediatria, Faculdade de Medicina, and ‡Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais; and †Departamento de Pediatria e Puericultura, Universidade Federal de Goiás, Goiânia, Brazil. Received for publication June 8, 2004; accepted September 7, 2004. Supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília, DF, Brazil, and Nestlé Brasil Ltda, São Paulo, Brazil. Reprints: Jacques R. Nicoli, PhD, Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, C.P. 486, 30161-970, Belo Horizonte, Minas Gerais, Brazil (e-mail: firstname.lastname@example.org). Journal of Clinical Gastroenterology: May-June 2005 - Volume 39 - Issue 5 - p 385-389 doi: 10.1097/01.mcg.0000159217.47419.5b Buy SDC Metrics Abstract Goals: This clinical trial was carried out to determine whether oral treatment with a commercial probiotic formula containing Bifidobacterium lactis and Streptococcus thermophilus would reduce the frequency of antibiotic-associated diarrhea (AAD) in infants. Study: In this double-bind formula controlled study, 80 infants, 6 to 36 months of age, were randomly assigned to receive a commercial formula containing 107 viable cells of B. lactis and 106viable cells of S. thermophilus at the initiation of antibiotics for a duration of 15 days. The infants were assessed daily for formula intake, stool frequency, and stool consistency for a total duration of 30 days. Seventy-seven infants received nonsupplemented formula for the entire duration. Results: There was a significant difference in the incidence of AAD in the children receiving probiotic-supplemented formula (16%) than nonsupplemented formula (31%). Conclusions: The present study shows that prevention against AAD in infants was obtained by oral treatment with daily dose of B. lactis and S. thermophilus. © 2005 Lippincott Williams & Wilkins, Inc.